Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.

Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

Exercise has been shown to improve numerous physical, psychosocial and clinical outcomes in those diagnosed with cancer.

Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.

We have observed the evolution of spatially fractionated radiotherapy (SFRT) primarily to manage metastatic cancer patients in the palliative care setting. Given recent advances in how SFRT can be delivered, can this therapeutic modality be optimized beyond the palliative care setting?

Updates in the treatment of pediatric neuroblastoma and Wilms Tumor are presented, highlighting recent practice-changing publications and evolving study questions.

Significant advances in systemic treatment options have positively impacted breast cancer survivorship.

This activity begins with discussion on optimal ways to identify high risk patients, approaches to patient education for all women, with a specific focus on those women disproportionately affected by BCRL/UED, and clinical workflows for high risk patients/those who have already developed BCRL/UED